Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-jr42d Total loading time: 0 Render date: 2024-04-25T02:11:46.031Z Has data issue: false hasContentIssue false

32 - Management of mesothelioma

Published online by Cambridge University Press:  05 November 2015

By
Louise Hanna ,
Jason Lester  and
Fergus MacBeth
Edited by
Louise Hanna ,
Tom Crosby  and
Fergus Macbeth
Louise Hanna
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff, UK
Jason Lester
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff, UK
Fergus MacBeth
Affiliation:
Cardiff University, Cardiff, UK
Louise Hanna
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Tom Crosby
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Fergus Macbeth
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Practical Clinical Oncology , pp. 427 - 435
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bissett, D., Macbeth, F. R. and Cram, I. (1991). The role of palliative radiotherapy in malignant mesothelioma. Clin. Oncol. (R. Coll. Radiol.), 3, 315–317.CrossRefGoogle ScholarPubMed
Bott, M., Brevet, M., Taylor, B. S., et al. (2011). The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet., 43, 668–672.CrossRefGoogle ScholarPubMed
BTS Statement. (2007). Statement on malignant mesothelioma in the UK. Thorax, 62, ii1–ii19.
Forster, K. M., Smyth, W. R., Starkschall, G., et al. (2003). Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. Int. J. Radiat. Oncol. Biol. Phys., 55, 606–616.CrossRefGoogle ScholarPubMed
Gatta, G., Ciccolallo, L., Kunkler, I., et al. (2006). Survival from rare cancer in adults: a population-based study. Lancet Oncol., 7, 132–140.CrossRefGoogle ScholarPubMed
Hubbard, R. (1997). The aetiology of mesothelioma: are risk factors other than asbestos exposure important?Thorax, 52, 496–497.CrossRefGoogle ScholarPubMed
Jaurand, M. C. and Fleury-Feith, J. (2005). Pathogenesis of malignant pleural mesothelioma. Respirology, 10, 2–8.CrossRefGoogle ScholarPubMed
Muers, M., Stephens, R. J., Fisher, P., et al. (2007). Active symptoms control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet, 371, 1685–1694.Google Scholar
National Statistics. (2005). Cancer Statistics and Registrations, Series MB1 no. 34. London: Office for National Statistics.
Parker, C. and Neville, E. (2003). Lung cancer 8: management of malignant mesothelioma. Thorax, 58, 809–813.CrossRefGoogle ScholarPubMed
Peto, J., Hodgson, J. T., Matthews, F. E., et al. (1995). Continuing increase in mesothelioma mortality in Britain. Lancet, 345, 535–539.CrossRefGoogle ScholarPubMed
Peto, J., Seidman, H. and Selikoff, I. J. (1982). Mesothelioma mortality in asbestos workers: implications for models of carcinogenesis and risk assessment. Br. J. Cancer, 45, 124–135.CrossRefGoogle ScholarPubMed
Rintoul, R. C., Ritchie, A. J., Edwards, J. G., et al. (2014). Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet, 384, 1118–1127.CrossRefGoogle ScholarPubMed
Rusch, V. W., Rosenzweig, K., Venkatraman, E., et al. (2001). A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg., 122, 788–795.CrossRefGoogle ScholarPubMed
Scherpereel, A., Astoul, P., Baas, T., et al. (2010). Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur. Resp. J., 35, 279–495.CrossRefGoogle ScholarPubMed
Steele, J. P., Klabatsa, A., Fennell, D. A., et al. (2005). Prognostic factors in mesothelioma. Lung Cancer, 49, S49–52.CrossRefGoogle ScholarPubMed
Sugarbaker, D. J., Garcia, J. P., Richards, W. G., et al. (1996). Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann. Surg., 224, 288–294.CrossRefGoogle ScholarPubMed
Travis, W. D., Brambilla, E., Muller-Hermelink, H. K., et al. (2004). World Health Organization Classification of Tumours. Pathology and Genetics, Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, pp. 125–144.Google Scholar
Treasure, T., Lang-Lazdunski, L., Waller, D., et al. (2011). Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol., 12, 763–772.CrossRefGoogle ScholarPubMed
UICC (2009). TNM Classification of Malignant Tumours, ed. Sobin, L. H., Gospodarowicz, M. K. and Wittekind, Ch., 7th edn. Chichester, Wiley-Blackwell, pp. 147–150.
Van Gelder, T., Damhuis, R. A. and Hoogsteden, H. C. (1994). Prognostic factors and survival in malignant pleural mesothelioma. Eur. Respir. J., 7, 1035–1038.Google ScholarPubMed
Vogelzang, N. J., Rusthoven, J. J., Simanowski, J., et al. (2003). Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.J. Clin. Oncol., 21, 2636–2644.CrossRefGoogle ScholarPubMed
Wagner, A. J., Bendell, J. C., Dolly, S., et al. (2011). A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. J. Clin. Oncol., 29, abstr. 3020.CrossRefGoogle Scholar
Yates, D. H., Corrin, B., Stidolph, P. N., et al. (1997). Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax, 52, 507–512.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×